Literature DB >> 19725157

Successful interferon desensitization in a patient with chronic hepatitis C infection.

Seyed Alireza Taghavi1, Ahad Eshraghian.   

Abstract

Treatment of hepatitis C, even when absolutely necessary, is almost impossible when interferon cannot be administered for any reason. We report a 65-year-old patient with chronic hepatitis C virus (HCV) infection and fibrosis, who was unable to receive interferon because of systemic hypersensitivity. The patient was desensitized successfully through gradual incremental exposure to interferon, and HCV infection was eradicated after a complete course of treatment, with no further allergic reactions. This case report that describes successful eradication of hepatitis C in a patient with advanced liver disease after desensitization to interferon revealed that desensitization may not necessarily damage the therapeutic efficacy of the drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19725157      PMCID: PMC2738819          DOI: 10.3748/wjg.15.4196

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  10 in total

Review 1.  Management of hepatitis C.

Authors:  Alfredo Alberti; Luisa Benvegnù
Journal:  J Hepatol       Date:  2003       Impact factor: 25.083

2.  A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone.

Authors:  G Saracco; A Ciancio; A Olivero; A Smedile; L Roffi; G Croce; C Colletta; G Cariti; M Andreoni; A Biglino; G Calleri; G Maggi; G F Tappero; P G Orsi; N Terreni; A Macor; A Di Napoli; E Rinaldi; G Ciccone; M Rizzetto
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

Review 3.  Epidemiology of hepatitis C.

Authors:  M J Alter
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

Review 4.  Liver transplantation and hepatitis C.

Authors:  M Willems; H J Metselaar; H W Tilanus; S W Schalm; R A de Man
Journal:  Transpl Int       Date:  2002-03-09       Impact factor: 3.782

5.  Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol.

Authors:  David Gammon; Pankaj Bhargava; Michael J McCormick
Journal:  Oncologist       Date:  2004

Review 6.  The changing epidemiology of hepatitis C virus infection in Europe.

Authors:  Juan I Esteban; Silvia Sauleda; Josep Quer
Journal:  J Hepatol       Date:  2007-11-05       Impact factor: 25.083

7.  The declining risk of post-transfusion hepatitis C virus infection.

Authors:  J G Donahue; A Muñoz; P M Ness; D E Brown; D H Yawn; H A McAllister; B A Reitz; K E Nelson
Journal:  N Engl J Med       Date:  1992-08-06       Impact factor: 91.245

8.  Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients.

Authors:  Seyed Moayed Alavian; Behzad Einollahi; Behzad Hajarizadeh; Siamak Bakhtiari; Mohsen Nafar; Sadegh Ahrabi
Journal:  Nephrology (Carlton)       Date:  2003-10       Impact factor: 2.506

9.  Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.

Authors:  G L Davis; R Esteban-Mur; V Rustgi; J Hoefs; S C Gordon; C Trepo; M L Shiffman; S Zeuzem; A Craxi; M H Ling; J Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region.

Authors:  Katayoun Samimi-Rad; Rakhshandeh Nategh; Reza Malekzadeh; Helene Norder; Lars Magnius
Journal:  J Med Virol       Date:  2004-10       Impact factor: 2.327

  10 in total
  1 in total

1.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.